Validating immunogenic SARS-CoV-2 peptides for novel T cell therapeutic approaches

November 15, 20212 min
Woman researcher carrying out scientific covid-19 test using microscope. Medical engineer using computer during global pandemic with coronavirus dressed in coverall.

T cell responses against SARS-CoV-2 may provide durable protection against infections, and T cells targeting the virus may be useful for COVID-19 treatments.

To best utilize T cells for prevention and treatment, it is critical to understand the viral targets, or peptides, that T cells recognize. To date, researchers have relied on in silico methods to predict immunogenic viral peptides, but little has been done to experimentally validate predicted targets.

Researchers led by Ke Pan, Ph.D., Yulun Chiu, Ph.D., and eCassian Yee, M.D., used mass spectrometry to sequence viral peptides from the surface of infected cells and verify which could elicit T cell responses. They demonstrated that many predicted peptides are not immunogenic and should not be pursued further. The team also identified new immunogenic peptides from highly conserved viral proteins, which do not mutate frequently, offering ideal targets for therapeutic approaches.

The researchers sequenced the T cell receptor (TCR) for one of these targets, allowing them to engineer the first reported TCR T cell capable of recognizing and targeting infected cells.

MJH footer logo with red letters

Medical Journal – Houston is the leading source of healthcare business news. With extremely relevant content, late-breaking news and monthly exclusives from industry experts, MJH News has created a winning combination of must-read editorial that physicians and hospital executives eagerly anticipate month after month. MJH News is the resource that provides everything they need in one place, and it is a high honor that they rely upon Medical Journal – Houston to keep their practice or hospital on the cutting edge.

Archives